Carboplatin and Paclitaxel Toxicity Profile

Hematologic Toxicities

Grade 3-4 neutropenia occurs in 37-48% of patients, according to the National Comprehensive Cancer Network 1
The American Society of Clinical Oncology recommends monitoring for neutropenia in patients receiving carboplatin and paclitaxel, with a reported incidence of grade 3-4 neutropenia in 37-48% of patients 1

Peripheral sensory neuropathy is the dose-limiting toxicity of paclitaxel, occurring in up to 47% of patients, as reported by the National Comprehensive Cancer Network 1
The risk of peripheral sensory neuropathy increases with cumulative exposure and pre-existing neuropathy or diabetes, according to the National Comprehensive Cancer Network 1

Gastrointestinal toxicity, including nausea, vomiting, and appetite loss, is a common side effect of carboplatin and paclitaxel, as reported by the National Comprehensive Cancer Network 2
Hypersensitivity reactions, including infusion reactions and true allergic reactions, can occur with carboplatin and paclitaxel, according to the National Comprehensive Cancer Network 3, 1
Renal and metabolic toxicity can occur with carboplatin and paclitaxel, although it is significantly less common than with cisplatin, as reported by the National Comprehensive Cancer Network 2
Fatigue is a common side effect of carboplatin and paclitaxel, according to the National Comprehensive Cancer Network 2

Elevated CRP and procalcitonin in patients receiving carboplatin and paclitaxel should prompt an investigation for alternative explanations, including infection, tumor-related causes, and other inflammatory processes, as recommended by the National Comprehensive Cancer Network 4, 2
Febrile neutropenia, which occurs in 4.8-12% of patients, can elevate both CRP and procalcitonin, according to the National Comprehensive Cancer Network 1
Bacterial infections secondary to chemotherapy-induced immunosuppression can elevate procalcitonin specifically, as reported by the National Comprehensive Cancer Network 4
Underlying malignancy itself can cause elevated CRP, according to the National Comprehensive Cancer Network 4
Tumor progression or necrosis may elevate inflammatory markers, as reported by the National Comprehensive Cancer Network 2

When encountering elevated CRP and procalcitonin in patients receiving carboplatin and paclitaxel, the National Comprehensive Cancer Network recommends checking complete blood count immediately to assess for neutropenia 1
Obtaining blood cultures if febrile or neutropenic is recommended by the National Comprehensive Cancer Network 1
Evaluating for clinical signs of infection, including respiratory, urinary, and catheter-related infections, is recommended by the National Comprehensive Cancer Network 4
Considering imaging if the source of infection is unclear is recommended by the National Comprehensive Cancer Network 3
The National Comprehensive Cancer Network recommends not attributing elevated CRP and procalcitonin to chemotherapy alone without excluding infection 2